GlassScriptPhysician profile
John W Campbell
NPI 1740395474
$10,546.96
in general payments reported to CMS, 2019-2025
52 companies · $1,898 in 2025
The $1,898 reported for 2025 was more than what 85% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,602 · 2020: $1,053 · 2021: $893 · 2022: $1,850 · 2023: $1,925 · 2024: $1,327 · 2025: $1,898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,126 · Education: $23.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,125.88 |
| Education | $23.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,594.68 | 2019-2025 | Cabenuva, Apretude, Rukobia |
| Janssen Biotech, INC. | $934.77 | 2019-2025 | Tremfya, Symtuza |
| Abbvie INC. | $917.22 | 2019-2025 | Mavyret, Dalvance, Avycaz |
| Gilead Sciences, INC. | $869.42 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $776.41 | 2019-2025 | Delstrigo, Pifeltro, Dificid |
| Ucb, INC. | $439.72 | 2019-2025 | Bimzelx, Cimzia, Fintepla |
| Insmed, INC. | $394.88 | 2022-2025 | Arikayce, Brinsupri |
| Horizon Therapeutics Plc | $347.59 | 2019-2023 | Krystexxa |
| Amgen INC. | $346.69 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $317.82 | 2019-2025 | Jynarque |
| Pfizer INC. | $283.98 | 2019-2025 | |
| Theratechnologies INC. | $277.31 | 2020-2025 | Trogarzo, Egrifta |
| Bayer Healthcare Pharmaceuticals INC. | $235.01 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $230.85 | 2019-2022 | |
| Astellas Pharma US INC | $163.59 | 2019-2020 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.